KarXT: A New Era in Antipsychotics?
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
KarXT: A New Era in Antipsychotics?
-
Narrated by:
-
By:
In this episode, we explore KarXT, a newly FDA-approved antipsychotic with a groundbreaking cholinergic mechanism, through the lens of a single powerful metric: the Number Needed to Treat. Could an NNT of 5 change how you approach treatment-resistant schizophrenia?
Faculty: Oliver Freudenreich, M.D.
Host: Richard Seeber, M.D.
- Learn more about our membership here
- Earn 0.75 CMEs: Quick Take Vol. 80
- How Effective Is KarXT (Xanomeline-Trospium) for Schizophrenia? NNT and NNH Explained
No reviews yet